{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:20:23Z","timestamp":1788801623287,"version":"build-2803163510"},"reference-count":60,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:p>\n            There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant\n            <jats:italic>Enterococcus<\/jats:italic>\n            (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against\n            <jats:named-content content-type=\"genus-species\">E. faecalis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">E. faecium<\/jats:named-content>\n            isolates using a dynamic\n            <jats:italic>in vitro<\/jats:italic>\n            bladder infection model. Eighty-four isolates underwent fosfomycin agar dilution susceptibility testing (\n            <jats:named-content content-type=\"genus-species\">E. faecalis<\/jats:named-content>\n            MIC\n            <jats:sub>50\/90<\/jats:sub>\n            32\/64\u2009\u03bcg\/ml;\n            <jats:named-content content-type=\"genus-species\">E. faecium<\/jats:named-content>\n            MIC\n            <jats:sub>50\/90<\/jats:sub>\n            64\/128\u2009\u03bcg\/ml).\n          <\/jats:p>","DOI":"10.1128\/aac.00342-20","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T14:01:36Z","timestamp":1585922496000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic\n            <i>In Vitro<\/i>\n            Model"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-6127","authenticated-orcid":false,"given":"Iain J.","family":"Abbott","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"van Gorp","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart","family":"van der Meijden","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixt A.","family":"Wijma","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands"},{"name":"Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia"},{"name":"School of Pharmacy, Centre for Translational Anti-infective Pharmacodynamics, The University of Queensland, Brisbane, Australia"},{"name":"Department of Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier, N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-4149","authenticated-orcid":false,"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia"},{"name":"Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000228"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.UTI-0012-2012"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-18"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2018.08.018"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00534-13"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.2.211"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00370-X"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702009000200010"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2082693"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.08.023"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00775-17"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00464-18"},{"key":"e_1_3_2_15_2","volume-title":"Monurol (fosfomycin tromethamine) package insert","author":"Forest Pharmaceuticals, Inc","year":"2011","unstructured":"Forest Pharmaceuticals, Inc. 2011. Monurol (fosfomycin tromethamine) package insert. Forest Pharmaceuticals, Inc., St Louis, MO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050717s007lbl.pdf."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000449422"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw178"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00402-12"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902811811"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1479397"},{"key":"e_1_3_2_21_2","volume-title":"CLSI M100","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing; 29th edition. CLSI M100. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_22_2","unstructured":"EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0 2019. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02099-12"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.09.008"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2020.105861"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2016.00014"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2311.171130"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078106"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01541"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-16"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx441"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv221"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.12.022"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2016.34"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1906169116"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302186"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01817-15"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.008"},{"key":"e_1_3_2_39_2","first-page":"466","article-title":"In-vitro activity of nitrofurantoin in enterococcus urinary tract infection","volume":"54","author":"Butt T","year":"2004","unstructured":"Butt T, Leghari MJ, Mahmood A. 2004. In-vitro activity of nitrofurantoin in enterococcus urinary tract infection. J Pak Med Assoc 54:466\u2013469.","journal-title":"J Pak Med Assoc"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.11.1136"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.03.001"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007266"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.10.010"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0628-7"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00222-3"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.01.013"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00362-9"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.01.014"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-17"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02627-17"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.137"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902967624"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2016.06.013"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-765X.1997.00378.x"},{"key":"e_1_3_2_55_2","volume-title":"CLSI M07","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; 9th edition. CLSI M07. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz519"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01982-19"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2017.07.036"},{"key":"e_1_3_2_59_2","unstructured":"U.S. Food and Drug Adminstration. 2018. Guidance for industry: bioanalytical method validation. https:\/\/www.fda.gov\/media\/70858\/download."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600581117"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00342-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00342-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:46:53Z","timestamp":1645480013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00342-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,21]]}},"alternative-id":["10.1128\/AAC.00342-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00342-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"2020-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00342-20"}}